Cervical cancer is an important cause of cancer-related deaths in women in developing countries. In Korea, cervical cancer is the third leading cancer among females and is fifth highest in mortality. The persistent oncogenic human papillomavirus (HPV) infections are the greatest risk of developing cervical intraepithelial neoplasia and invasive cancer. The overall prevalence of HPV was 10.4% in Korea and strong risk factors for HPV infection included a young age at sexual debut. The National Cancer Screening Program, which includes cervical cancer screening, has the following principles: the main screening tool is the Papanicolaou test conducted by gynecologists, which targets all women age 30 and over, and which is done every 2 years. HPV DNA tests have not yet been permitted as a screening test for cervical cancer in Korea; however, these are conducted along with a Pap test for screening cervical cancer in the clinic. The use of prophylactic HPV vaccine has been accepted in Korea; The Korean Society of Gynecologic Oncology and Colposcopy's recommendation for routine vaccination is for females aged 15-17 years with a catch-up vaccination recommended for females aged 18-26 years who have not been previously vaccinated. However, many people in Korea are not familiar with the HPV vaccine. Therefore, it is necessary to improve awareness for the disease and HPV vaccination and to establish the effective strategies to obtain funding for HPV vaccination. In the future, cervical cancer is expected to disappear throughout the world, including the Asia Pacific region, through a combination of vaccination and qualified screening programs for cervical cancer.
INTRODUCTION
Cervical cancer is the leading cause of cancer-related death in the female population worldwide. In 2006, about 500,000 cases of cervical cancer were newly diagnosed and more than 280,000 deaths occurred (World Health Organization). During the past 4 decades, the incidence and mortality from cervical cancer have declined significantly primarily because of the widespread use of the Papanicolaou (Pap) test as a screening test to detect cervical abnormalities, and the speed of decline has decreased so that it appears to have plateaued at present. However, a higher incidence rate is still being observed in developing countries. Human papillomavirus (HPV) is the primary cause of cervical neoplasia. More than 100 types of HPV have been found and are classified as high-risk or low-risk types according to their oncogenicity. 1 HPV 16 and 18 cause 70% of cervical cancers, while HPV 6 and 11 cause most of genital warts, or condylomas. 2, 3 At present, a prophylactic vaccine has been developed and is now utilized worldwide, and there are many ongoing studies for a therapeutic vaccine. It is expected that the incidence of cervical cancer will decrease rapidly in future because of the HPV vaccine. However, cervical cancer is still a significant problem, especially in developing countries and resource-insufficient areas such as Africa, Asia, Central and South America. [4] [5] [6] This is partially related to poor availability of health care, which is induced by social and cultural barriers that decrease patient compliance and interrupt physician education. 7, 8 It is also related to the fact that HPV vaccines will be first introduced into industrialized countries and only later in developing countries. In its aspects of incidence and mortality of cervical cancer, Korea has the pattern of a developing country. In this article, we will first describe the prevalence and risk factors of cervical cancer in Korea, and then will introduce the current situation of cervical cancer prevention and availability of HPV vaccine in Korea. . The overall prevalence of HPV infection was 12.6 (389/3091) and calculated 15.5% when standardized. The prevalence of HPV infection was 24.1% (14/58), 14.3% (64/446), 13.7% (165/1,206), 9.5% (93/977), 13.3% (50/376) and 10.7% (3/28) in the third, fourth, fifth, sixth, seventh, and eighth decade of age, respectively. The prevalence of HPV infection was significantly higher in patients between 20 and 30 yr than in other age groups (p=0.003). (Shin HR et al. 28 ). Distribution of cytological findings was as follows: Normal was 95.3%, ASCUS was 2.1%, LSIL was 1.9%, HSIL was 0.4%, Carcinoma in situ was 0.1% and Invasive cervical cancer was 0.2%. Overall, 90 women (10.4%) were positive for HPV DNA. HPV prevalence was 8.5% among cytologically normal women, 22.2% among those with ASCUS, 52.9% among those with LSIL and 100% among 7 women with HSIL or worse. The most common HPV types were HPV 70, HPV 16 and HPV 33. ASCUS: atypical squamous cells of undetermined significance, LSIL: low-grade squamous intraepithelial lesion, HSIL: high-grade squamous intraepithelial lesions. HPV prevalence in Korean women has been investigated in numerous studies. It has been found to be diverse according to age groups, areas, socioeconomic status, and methods for detection of HPV DNA, from 10% to over the range of 40%. However, most reports have shown that the overall prevalence of HPV infection was 10-15%. The incidence of HPV infection was significantly higher in females between 20 and 30 years than in other age groups and the rate of abnormal Pap smears was significantly higher in HPV positive groups than in HPV negative groups. Through the research with women who visited a Health Promotion Cancer study in 2002, Joo et al. 14 reported that the overall prevalence of HPV infection was 
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RISK FACTORS FOR HPV INFECTION IN KOREA
In Korea, one out of ten women is infected with HPV in the general female population according to two surveys carried out in 2000 and 2002 in the town of Busan. The prevalence was much higher in young women than in middle-aged women. 15, 28 The International Agency for Research on Cancer (IARC) HPV prevalence survey in Busan, Korea, with a random age-stratified sample of the general female population, revealed that young age, currently smoking cigarettes, having multiple lifetime sex partners and a husband's extramarital relationships were strong risk factors for HPV infection. 15, 28 HPV is a common pathogen resulting from sexually transmitted infection; therefore, risk factors for HPV exposure are related to patterns of sexual behavior. Young women in South Korea start to have penetrative sex relatively late (median age: 18 years). Table 1 years old and less than 40% of these young people used contraceptive methods for penetrative sexual intercourse. 30 The young people of this generation seem to have different concepts of sexual behavior compared with the past generations, and these changes influence HPV exposure and the prevalence of cervical cancer. According to reports from The Korean Society of Preventive Medicine, risk factors for cervical cancer in Korea are socioeconomic status, familial history, number of sexual partners, and age at first sex, etc. In females with a history of pregnancies, the risk of developing cervical cancer is 5 to 6 times greater compared with that of a nullipara. If there is familial history of cervical cancer, the risk is 2 times greater. An increased risk of cervical cancer is also associated with age at first sex at less than 20 years old.
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CURRENT SITUATION OF CERVICAL CANCER SCREENING IN KOREA
The Pap test is still the most common cancer screening test in Korea despite it being 50-year old technology. Cervical cancer screening with the Pap test was first introduced in the late 1950s in Korea and adopted as a Health Screening for Medical Insurance Beneficiaries as of 1988; however, the Pap screening rate has been kept at very low level; about 34% in 1998 (in women age 20 and over, ever screened during the last 2 years). In 1999, the National Cancer Screening (NCS) Program was started only for Medicaid for stomach, breast and cervical cancers, which was extended in 2002 to those with the lower 20% premium of the National Health Insurance Corp (NHIC). The Korea Health Insurance Corp. covered cervical cancer screening in 9.6% of the target population in 2001, and this proportion has been increasing stepwise. The NCS Programs have expanded their target population as well as target diseases and, at present, support cancer screening tests to those on Medicaid and those with the lower 50% premium of NHIC for stomach, breast, cervical, hepatic and colorectal cancers. According to the National Health and Nutrition Survey, the overall participation rate for cervical cancer screening was estimated at approximately 40% and showed an increase from 22.4% in 1998, 39.8% in 2001, to 41.5% and the participation rate was the highest in women aged 40- (Table 2 ). This guideline is different from several consensus guidelines developed worldwide in many aspects; the target population is older, the testing interval is longer and there is no recommendation for a HPV DNA test. In fact, the Korean Society of Obstetrics and Gynecology recommends another cervical cancer screening schedule: a Pap test every a year for women 21 years and over (Table 2 ). However, the National Cancer Screening Program should be planned considering availability and cost-effectiveness in order to maximize its own efficacy; therefore, it can be different from the guidelines of an academic society.
In a meta-analysis of 94 studies, 35 the sensitivity of Pap testing ranged from 30 to 87%, and the specificity ranged from 86 to 100%. Shin et al. 36 reported 71.2% sensitivity and 97.7% specificity in Korea through an analysis comparing cervical cytology versus histological findings of 1,023 women. Another study reported that the sensitivity of the Pap test ranged from 70.5 to 83% in Korea; however, the results showed diversity according to institution. 37 A number of factors, including small lesion size, inadequate sampling, obscuring blood and debris, and results specific to individuals, limit the sensitivity of the conventional Pap test. In an attempt to improve sample CIN2+: cervical intraepithelial neoplasia grade 2 or more severe, AIS: adenocarcinoma in situ, *Defined as "The total vaccinated cohort included women who had prevalent infection with oncogenic HPV often with several types, as well as low-grade cytological abnormalities at study entry and who received at least one vaccine dose.", †
Defined as "all women who were seronegative and PCR-negative to HPV 16, HPV 18 or both at day 1, including those who received incomplete vaccination regimens, were exposed to HPV 16/18 before receiving three doses or who had major protocol violations." showed prophylactic efficacy of more than 90% against persistent infection by HPV, abnormal cytology, and cervical intraepithelial neoplasia associated with HPV16 or HPV18 (Table  3) . Therefore, these could be used for cervical cancer prevention. The Korean Food and Drug Administration (KFDA) approved Gardasil TM for the prevention of cervical cancers and genital warts in June 2007 and Cervarix TM for the prevention of cervical cancers in July 2008. Many factors should be considered for determining guideline of routine HPV vaccination; for example, the period of prevention for HPV infection through vaccination, the mean age at sexual debut, the effective time of injection and national financial affairs. If the age of routine vaccination is early, the possibility of prevention of HPV infection might be higher, however the cost for a booster injection could increase. Even if it is the most desirable that HPV vaccination be included in a school immunization program, this is impossible at present because of the high cost. Therefore, it is important to consider the age at sexual debut and the cost-effectiveness within national financial affairs or private medical insurance. There is no financial support at present for HPV vaccination from any national policy in Korea. Considering the amount of information about HPV vaccine and the special conditions in Korea, a clinical guideline for HPV vaccination for prevention of cervical cancer was recommended by KSGOC (Table 4) .
CONCLUSIONS
Cervical cancer remains a significant cause of cancer-related deaths in women worldwide, especially in Asia and including Korea. However, screening tests for cervical cancer have reduced the disease burden by up to 75% in countries that have carried out excellent screening programs. A quadrivalent HPV vaccine and a bivalent HPV vaccine have been developed for the prevention of cervical cancer related HPV infection and the use of these has now been approved in Korea. However, many people are not familiar with the HPV vaccine primarily due to high costs and lack of adequate understanding. Therefore, increased disease awareness and utilization of screening is the first priority for controlling cervical cancer. Following this, it will be important to establish effective strategies to obtain funding for HPV vaccination, in addition to the efforts to decrease the cost of vaccination. In the future, cervical cancer is expected to disappear throughout the world in much the same manner as polio has through vaccination programs.
